198 related articles for article (PubMed ID: 37005212)
21. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
22. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.
Huang J; Wang Y; Xu F; Wang Z; Wu G; Kong W; Cheoklong NG; Tricard T; Wu X; Zhai W; Zhang W; Zhang J; Zhang D; Chen S; Lian Y; Chen Y; Zhang J; Huang Y; Xue W
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38862251
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T3a Renal Masses: A Multicenter Analysis.
Yim K; Aron M; Rha KH; Simone G; Minervini A; Challacombe B; Schips L; Berardinelli F; Quarto G; Mehrazin R; Patel D; Patel S; Bindayi A; Ashrafi AN; Desai M; Alqahtani A; Gallucci M; Sulek J; Mari A; De Luyk N; Anele U; Autorino R; Porpiglia F; Sundaram CP; Gill IS; Perdona S; Derweesh IH
Eur Urol Focus; 2021 Sep; 7(5):1107-1114. PubMed ID: 33249089
[TBL] [Abstract][Full Text] [Related]
27. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
28. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
Kuusk T; Abu-Ghanem Y; Mumtaz F; Powles T; Bex A
Curr Opin Urol; 2021 May; 31(3):262-269. PubMed ID: 33742979
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma.
Kuusk T; Bex A
Hematol Oncol Clin North Am; 2023 Oct; 37(5):907-920. PubMed ID: 37369611
[TBL] [Abstract][Full Text] [Related]
30. Operative safety and oncologic outcome of laparoscopic radical nephrectomy for renal cell carcinoma >7 cm: a multicenter study of 222 patients.
Luciani LG; Porpiglia F; Cai T; D'Elia C; Vattovani V; Giusti G; Tiscione D; Chiodini S; Peschechera R; Fiori C; Spina R; Parma P; Celia A; Malossini G
Urology; 2013 Jun; 81(6):1239-44. PubMed ID: 23608667
[TBL] [Abstract][Full Text] [Related]
31. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
32. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
33. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
[TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
[TBL] [Abstract][Full Text] [Related]
35. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.
Mori K; Quhal F; Yanagisawa T; Katayama S; Pradere B; Laukhtina E; Rajwa P; Mostafaei H; Sari Motlagh R; Kimura T; Egawa S; Bensalah K; Karakiewicz PI; Schmidinger M; Shariat SF
Int Immunopharmacol; 2022 Jul; 108():108720. PubMed ID: 35339843
[TBL] [Abstract][Full Text] [Related]
36. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
37. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
[TBL] [Abstract][Full Text] [Related]
38. The operative safety and oncological outcomes of laparoscopic nephrectomy for T3 renal cell cancer.
Stewart GD; Ang WJ; Laird A; Tolley DA; Riddick AC; McNeill SA
BJU Int; 2012 Sep; 110(6):884-90. PubMed ID: 22289017
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
40. Developments in personalized therapy for metastatic renal cell carcinoma.
Fujiwara R; Kageyama S; Yuasa T
Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
